The development of a vaccine against malaria is a major research priority given the burden of disease, death and economic loss inflicted upon the tropical world by this parasite. Despite decades of effort, however, a vaccine remains elusive. The best candidate is a subunit vaccine termed RTS,S but this provides only partial protection against clinical disease. This review examines what is known about protective immunity against pre-erythrocytic stage malaria by considering the humoral and T cell-mediated immune responses that are induced by attenuated sporozoites and by the RTS,S vaccine. On the basis of these observations a set of research priorities are defined that are crucial for the development of a vaccine capable of inducing long-lasting and high-grade protection against malaria.
The scope of the problem Malaria is caused by the protozoan genus Plasmodium and is responsible for 700 000 to 1 000 000 deaths per year in tropical regions of the world, most severely affecting children in sub-Saharan Africa [1] . Naturally acquired immunity to malaria is slow to develop, non-sterilizing and short-lived in the absence of continuous exposure. The parasite rapidly develops resistance to anti-malarial drugs and treatment is often followed by reinfection [2] . Hence, there is an urgent need to develop a malaria vaccine.
This task has proven difficult: after decades of effort, the only candidate vaccine approaching licensure is RTS,S [3] , a virus-like particle, based on the dominant surface protein [designated the circumsporozoite protein (CS protein)] of the Plasmodium falciparum (Pf) sporozoite. RTS,S has the potential to provide a significant health benefit if the reductions in clinical illness seen in early field trials are confirmed in the Phase III trial currently underway in nine countries across sub-Saharan Africa [3] . However, RTS,S does not appear potent enough to prevent infection completely in the majority of vaccine recipients, inducing only partial immunity. To design a vaccine providing lifelong, sterile protection, it will be important to understand better the interface of the parasite with the human immune system, including its immune-evasion mechanisms. This objective is especially relevant for the early (preerythrocytic) sporozoite and liver stages of the infection where the induction of sterilizing immunity would completely prevent blood stage malaria and thus both clinical illness and transmission.
This review highlights what is known about the immunological responses to the pre-erythrocytic stages of the parasite, focusing on two models of protection: immunization with attenuated sporozoites and immunization with the CS protein. It then identifies key research questions to guide the development of a highly effective pre-erythrocytic stage vaccine.
The sporozoite
When an infected female Anopheles mosquito bites, it injects several hundred sporozoites into the cutaneous tissue. Over the next minutes to hours some of the sporozoites leave the injection site and enter blood vessels where they are carried rapidly to the liver, while others remain in the skin or travel to regional lymph nodes or to the spleen. On reaching the liver, sporozoites cross the endothelium, in some cases passing through Kupffer cells (KC), and then traverse several hepatocytes before entering a terminal hepatocyte via an invagination process, leading to the formation of a parasitophorous vacuole in which each sporozoite differentiates into liver stage and finally blood stage parasites [4] [5] [6] (Figure 1 ). As the sporozoite passes through a hepatocyte it can cause cell wounding [4] and in some instances necrosis, although whether or not this constitutes a danger signal for the immune system is unclear. The liver stage of infection appears otherwise to be relatively immunologically silent, possibly due to the minor antigen (Ag) load, the immunetolerant nature of the liver, and/or the immune-regulatory mechanisms initiated during sporozoite passage through the skin [7] .
The attenuated sporozoite human protection model In 1973 it was demonstrated that humans subjected to approximately 1000 to 2000 irradiated and Pf sporozoiteinfected mosquito bites, followed by primary challenge within 10 weeks after immunization, were protected and the protection lasted for up to 10 months against sporozoite re-challenge [8, 9] . This work followed studies where immunization of animals with radiation-attenuated sporozoites was similarly highly protective [10, 11] . Recently, immunization of rodents with genetically attenuated sporozoites (GAS) also afforded high-grade (>90%) protection [12] . Given the powerful immunity induced by attenuated The parasites glide along the sinusoid, sometimes moving against the flow of blood, until they encounter a Kupffer cell. After a pause, they slowly pass through the Kupffer cell and cross the space of Disse beyond it. Once inside the liver parenchyma, the parasites increase their velocity and migrate for many minutes through several hepatocytes, before they eventually come to rest in a terminal hepatocyte to initiate development (panel reproduced with permission from [5] ). (b) An infected female Anopheles injects up to several hundred sporozoites into the cutaneous tissue while feeding. Some of the sporozoites leave the injection site and enter blood vessels where they are carried to the liver. Some of the sporozoites invade hepatocytes (panel (a)) where they undergo asexual multiplication (schizogony) and develop into thousands of merozoites. The merozoites exit the infected hepatocyte in membrane-bound vesicles (merosomes or extrusomes) which, following rupture, enable the merozoites to rapidly invade red blood cells thereby initiating blood-stage malaria. During the blood stage, formation of gametocytes also occurs and these are ingested by a feeding mosquito to initiate the next cycle.
Report Documentation Page
sporozoites, much effort has been expended to identify the underlying protective mechanisms, including the antigenic targets. Radiation-attenuated sporozoites (RAS), as do native sporozoites, invade hepatocytes and form a parasitophorous vacuole, but their development is arrested at the early liver stages [13] , creating a repository of early liver stage Ags which could serve to induce and maintain protracted immunity. The relatively persistent Ag load is one factor that distinguishes immunization with attenuated sporozoites from exposure to intact sporozoites under natural conditions. The CS protein and probably other parasite Ags cross the vacuolar membrane, possibly via a 'gatekeeper complex' [14] , to enter the cytoplasm where they undergo processing and subsequent presentation on the hepatocyte surface. It has been demonstrated that sporozoite-infected hepatocytes can process and present Plasmodium berghei (Pb) CS-protein epitopes to T cells [15] , although it is also possible that sporozoites and liver-stage Ags egress from the cell to be ingested and processed by dendritic and other Ag-presenting cells. Likewise, some of the RAS entering the liver are directly taken up by dendritic cells (DC) for processing and presentation to T cells. It is probable that multiple antigens are involved in protection, in as much as CS protein contributes to but is not required for protection, because mice tolerized to CS protein can still be protected by RAS [16] .
The RTS,S human protection model
The surface of the sporozoite is densely packed with protein. The most prominent is the CS protein which is shed as the parasite undergoes motility [17] and cell traversal [18] . The Pf CS protein has N and C terminal regions which flank a central repeat region consisting of 38 to 40 copies of the B cell epitope NANP, preceded by a minor central repeat sequence of alternating NVDP and NANP. Several CD4 and CD8 T cell epitopes have been mapped to the C terminus of the CS protein, and some of these are universal epitopes [19] [20] [21] [22] . Currently, there are also extensive efforts to identify additional sporozoite proteins [23] [24] [25] .
The relatively potent immunogenicity and prominent location on the sporozoite surface have made the CS protein a leading candidate Ag for malaria vaccines. Following the demonstration that CS-protein-based vaccines can induce protection in animals, the RTS,S vaccine was developed to extend this protection to humans [3, 26] . RTS,S consists of the central repeat region and the C terminus of the Pf CS protein fused to the surface Ag of hepatitis B virus; this is coexpressed with free surface Ag to form an hepatitis B surface (HBs) Ag-like particle. RTS,S has been formulated in different adjuvants including ASO2A, an oilin-water emulsion containing QS-21 (a derivative of the saponin Quil A) and mono-phosphoryl lipid A, and ASO1B, which is a liposome formulation. The RTS,S vaccine confers sterile immunity to 40-50% of malaria-naïve subjects against a primary sporozoite challenge, and 40-50% of subjects protected against the primary challenge are also protected against rechallenge 5 months later [27] . The Aband cell-mediated immune responses to RTS,S have been characterized extensively in both protected and non-protected human volunteers [27, 28] .
Ab-mediated immunity
There is evidence that humoral immunity contributes to protection against pre-erythrocytic stage malaria. Passive transfer of monoclonal Ab specific for the central repeat regions of Pb and P. yoelii (Py) CS protein protects mice against sporozoite challenge [29, 30] . Immune serum from sporozoite-immunized humans can also block the invasion of Pf sporozoites into hepatocytes [31] . In addition, the RTS,S vaccine induces high titers of CS-protein-specific Abs that correlate with protection against infectious challenge. The mechanism underlying Ab-mediated protection could involve inhibition of hepatocyte invasion or opsonization of sporozoites for uptake by macrophages and DC. Recent studies [32] have also shown that sporozoites injected into the dermis of immunized mice are immobilized and become degraded within hours. Moreover, mosquitoes introduce fewer sporozoites into immunized as compared to non-immunized mice, presumably due to the formation of Ag-Ab complexes in the proboscis [32] . Consequently, RTS,S-induced Abs probably also inhibit sporozoite motility.
Because sporozoites invade hepatocytes soon after injection, sufficiently high titers of sporozoite-specific Abs must be present at the time of injection for Abs to confer protection. This implies a need for sustained Ab production by long-lived plasma cells (PC) (Figure 2 ). The activation of these cells appears to involve Ags expressing both a repetitive epitope to mediate high B cell receptor cross-linking and T cell epitopes to induce the activation of follicular Thelper (T FH ) cells [33] . Particular attenuated virus vaccines meet these criteria and can induce Ab responses that persist for decades without apparent re-boosting [34, 35] . Long-term storage of Ag-Ab-complement complexes on follicular DC [36] could also be required.
For the RTS,S vaccine the majority of non-protected volunteers make much weaker CS-protein-specific Ab responses than protected volunteers. In addition, CS-protein-specific Ab titers fall substantially with time after the 3 rd dose, even when accompanied by natural boosting [37] . Hence, mechanisms that sustain high Ab titers would probably also improve long-term vaccine efficacy. In general, higher primary Ab titers and longer intervals between boosting tend to favor longer-lived Ab responses, and it would therefore be worth evaluating at 0, 1, and 6 months instead of in the standard 0, 1, and 2 months immunization schedule. There is also evidence [38] that high avidity Abs are more protective than low-avidity Abs, thus methods to increase Ab avidity would probably improve RTS,S-induced protection.
CD4 T cell immunity
There is evidence that CD4 T cells also protect against the pre-erythrocytic stages of malaria. CD4 T cells specific for a Py CS-protein epitope can both eliminate infected hepatocytes in vitro and adoptively transfer protection in vivo [39] . As mentioned, the RTS,S vaccine induces high titers of CS-protein-specific IgG Abs, and this probably depends on the activation of CS-protein-specific CD4 T FH cells. RTS,S-primed CD4 T cells can also be recalled with CSprotein peptides to produce IFN-g [27] , a known inhibitor of intracellular stages of the parasite [40] . Moreover, the frequency of the RTS,S-induced IFN-g + CD4 T cells was higher in protected than in non-protected volunteers [27] .
Studies of other pathogens in both mice [41] and humans [42] indicate that multifunctional CD4 T cells simultaneously producing IL-2, IFN-g and TNF-a more strongly associate with protection than bi-or mono-functional CD4 T cells. This could be due to the capacity of IL-2 to promote lymphoproliferation and hence maintain the lineage and the capacity of IFN-g and TNF-a to act synergistically. In addition, the intensity of IFN-g secretion from multifunctional cells appears to be greater than that of terminal effector cells. Seder et al. [43] They propose that an ideal vaccine will be strong enough to drive CD4 T cells to differentiate into IL-2 + TNF-a + IFN-g + triple producers (referred to as the 'sweet spot'), but not so strong as to further differentiate them into terminal effectors. The CD4 T cell lineage also includes regulatory T (T reg ) cells which are generally controlled by the transcription factor FOXP3 (reviewed in [44] ) and which limit excessive inflammation and inhibit sterilizing immunity to pathogens. For example, T reg cells prevent effector T cells from completely eliminating Leishmania parasites from the site of infection, and the persistence of residual parasites contributes to the maintenance of long-term immunity [45] . There are several reports that T reg cells control immune responses to blood stage malaria [46, 47] and, although there is no direct evidence, they could also regulate responses to the pre-erythrocytic stages. It is clear that future immunization strategies might have to consider whether a vaccine activates T reg cells in addition to effector and memory T cells and, if this is the case, identify a method to counteract the effects of T reg cells such as the coadministration of an immunomodulatory drug [46] .
CD8 T cell immunity
Although Abs and CD4 T cells contribute to protection, CD8 T cells appear to be the sine qua non effectors that confer sterile immunity in some strains of attenuated sporozoite-immunized mice. Thus, for example, depletion of CD8 + cells from RAS-immunized BALB/c mice before challenge abrogates protection. In addition, CD8 transgenic T cells specific for Py CS protein can secrete IFN-g in response to and protect mice against sporozoite challenge. Recently it has been demonstrated that GAS immunization of mice also activates CD8 T cells that are required for protection [48] and which can effect contact-dependent killing of Py-infected hepatocytes [49] .
CD8 T cells specific for Pf CS protein have also been found in the blood of both RAS-immunized volunteers and naturally exposed subjects [21, 50] . In addition, investigators working at the University of Oxford have explored the use of vaccines encoding the pre-erythrocytic stage thrombospondin-related adhesion protein Ag (TRAP) fused to a string of linked T-and B-cell epitopes (ME-TRAP), and showed that priming humans with a construct of chimpanzee (Ch) adenovirus 63 encoding ME-TRAP (AdCh63-ME-TRAP), followed by a boost with a modified vaccinia Ankara (MVA) construct MVA-ME-TRAP, induced strong CD8 g-interferon-secreting T cell responses and the associated efficacy data has been submitted for publication (Ewer et al., submitted, Adrian Hill, personal communication).
There is evidence that some sporozoites migrate from the dermis to the draining lymph node where they activate CS-protein-specific CD8 T cells [51] . These CD8 T cells subsequently travel to the liver where they could contribute to pre-erythrocytic stage immunity. It is more likely, however, that attenuated sporozoites also induce CD8 T cells that are specific for the liver-stage Ags developing only in infected hepatocytes.
Attenuated sporozoites activate CD8 T cells, whereas native sporozoites do not, and this could be related to the former causing infected hepatocytes to undergo apoptosis [52, 53] . The apoptotic cells are probably taken up by intrahepatic CD8 + DC for cross-presentation of liver-stage Ags to CD8 T cells [54] . This mechanism, however, has been called into question [55] , in part because native sporozoites can also induce sterile immunity in humans when administered with chloroquine to prevent blood stage infection [56] , although there is the additional proviso that immunity in this case could have been directed primarily against very early blood stages that exit the liver. Protection, in this case, appears to be mediated by multi-functional effector memory T (T EM ) cells, and chloroquine could have potentiated the activation of these cells [57] .
In general, acute infection of humans or mice with a pathogen causes CD8 T cells to undergo rapid expansion to generate a large population of effector cells. Upon pathogen clearance, the cells undergo rapid contraction when most of the cells die by apoptosis. However, 5-10% of the effector cells survive and form long-lived memory CD8 T cells. [58, 59] . Surprisingly, the CD8 T E/EM cells do not undergo contraction after the last boost/immunization or after sporozoite challenge, even after a prolonged period of time. It is conceivable that the lack of contraction is due to chronic Ag stimulation, and this would be consistent with RAS immunization generating a persisting Ag depot. It is not clear whether protection against sporozoite challenge requires the protracted presence of CD8 T E cells that could respond immediately to infection. If, by contrast, protection depends on CD8 T CM cells that can only be recruited from a draining lymph node, there could be insufficient time for these cells to recognize new parasite Ag, multiply to high numbers, and migrate to the liver to kill the parasite. Conversely, if CD8 T CM cells are maintained in the liver, temporal constraints might not apply. One of the key questions for the development of a malaria subunit vaccine is, therefore, whether protection against sporozoite challenge requires persisting CD8 T E cells or CD8 T CM cells and, if the former, whether the maintenance of these cells depends on a persisting depot of Ag. It is worth noting that primaquine treatment to eliminate persisting liver-stage Ag before the development of longlived memory cells abolished protection in both RAS [60] and GAS [61] -immunized animals.
Valuable data regarding the role of central versus effector memory CD8 T cells have been provided by investigators at the University of Oxford. Volunteers were immunized with ME-TRAP; DNA and fowlpox constructs were used for priming, and an MVA construct provided the boost. In some cases, vaccine-induced reduction in liverstage burden correlated more closely with long-term (cells cultured for 9 d) than with short-term (cells cultured for 18 h) responses as measured by enzyme-linked immunospot (ELISPOT) assay, indicating that T CM cells present at the time of sporozoite challenge could make a greater contribution to protection than T EM cells [62, 63] . A principal hindrance to answering these questions in the RAS model is our lack of knowledge of the Ags expressed by the liver stage of the parasite. Consequently, extensive efforts employing both genomics and proteomics are being directed to discovering relevant liver stage Ags [23] [24] [25] . For example, 16 novel Pf proteins have been recently identified which peripheral blood mononuclear cells (PBMC) from RAS-immunized volunteers recognized more frequently than 'traditional' Pf Ags such as the CS protein and exported protein-1 (EXP-1) [64] . Moreover, two of these 16 Ags elicited higher responses from protected versus non-protected volunteers.
Once the mechanisms that enable attenuated sporozoites to induce sterile CD8 T-cell-mediated immunity are understood, attempts could be made to trigger similar immune mechanisms by a subunit vaccine. The initiation of the appropriate activation pathways will probably occur in the lymph node draining the vaccination site. Figure 3 illustrates the cellular interactions that lead to the activation of short-lived effector CD8 T cells (SLECs), memory potential effector CD8 T cells (MPECs) and memory CD8 T cells, as well as the migration of these cells from the lymph node to the liver to mediate their effector function. Figure 3 . Induction of T cell mediated immunity. Region 1: a subunit vaccine -in this case a liver-stage antigen (Ag) coupled to a pathogen-associated molecular pattern (PAMP) -is taken up into an endosome by an Ag-presenting cell (APC). The PAMP interacts with a pattern-recognition receptor (PRR), either on the cell surface or within the endosome, and this stimulates the maturation of the APC. Region 2: Ag within early endosomes is degraded and binds to nascent class II molecules for transport to the cell surface. Recognition of the peptide class II complex, followed by co-stimulation (Co St), induces the activation of Ag-specific CD4 T cells and these cells license the APC and enable it to activate CD8 T cells. Region 3: some Ag is translocated out of the endosome into the cytoplasm where it is degraded into peptides by the proteosome. The peptides are transported into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) where they are bound to nascent class I molecules and then trimmed to size by the ER aminopeptidase (ERAP) enzymes. The peptide class I complexes are then transported to the cell surface. Region 4: the peptide class I complexes are recognized by Ag-specific CD8 + T cells which undergo proliferation under the influence of costimulation and APC-derived IL-12. The proximal daughter upregulates the T box expressed in T cells transcription factor (T-BET) and Blimp-1 and develops into a short-lived effector cell (SLEC) while the distal daughter becomes a long-lived memory CD8 T (T M ) cell. Region 5: during CD8 T cell expansion some effector cells do not down regulate CD127, and under the influence of IL-7 differentiate into memory potential effector cells (MPECS). Region 6: the sporozoite migrates through the Kupffer cell (KC) and several hepatocytes to lodge in a terminal hepatocyte within a parasitophorous vacuole. The CD8 effector T cells leave the lymph node and migrate to the space of Disse or into the sinusoid of the liver. They recognize parasite Ag plus class I on the surface of the infected hepatocyte and elaborate IFN-g and perforin/granzyme (P/G) to kill the parasite. Region 7: as a result of cell traversal or of protein shedding, KC and other APC also process and present parasite Ags to activate CD4 and CD8 T cells in the sinusoid of the liver. These cells produce TNF-a which can also act at a distance to kill the parasite. The cytokine milieu of the liver might also promote the activation of regulatory T cells (T reg ), and these could secrete IL-10 to suppress the activation of effector T cells.
TRENDS in Parasitology
Key research questions RTS,S vaccine trials have shown that both Abs and CD4 T cells specific for the CS protein confer sterile immunity to about 50% of malaria-naïve volunteers and partial immunity to children in endemic areas. RAS sporozoite vaccines also confer sterile immunity and, in the mouse model, CD8 T cells specific for currently unidentified liver stage Ags appear to be the key mediators of protection. Most recently, data from a fowlpox prime and MVA boost regimen (using the ME-TRAP antigen) suggest that T lymphocytes can provide sterile immunity in humans in the absence of significant antibody responses [65] . Hence, there appear to be multiple immune responses that can be harnessed to achieve pre-erythrocytic stage immunity. Key outstanding questions regarding the induction and maintenance of protective immunity to pre-erythrocytic stage antigens are listed in Table 1 .
Conclusions and future directions
Long-term maintenance of high titers of sporozoite surfaceAg-specific Abs will be an important component of the protective immunity induced by vaccines, probably depending upon the generation of long-lived PCs. In general, stronger primary Ab responses correlate with stronger and more long-lived booster responses, and therefore adjuvants and vaccine platforms that favor strong primary responses could contribute to the longevity of the Ab response. Longer times between prime and boost immunizations also favor long-lived Ab production [66] . Enhancing the expression of the transcription repressor Blimp-1, which promotes the differentiation of B cells into long-lived PC [67] , might be achieved by activating IL-21-secreting T FH cells, and this could also favor durable Ab production. An effective malaria vaccine should also induce strong and long-lasting pre-erythrocytic stage T cell immunity.
The identification of the most protective pre-erythrocytic stage Ags is a primary objective. It will be necessary to establish whether intra-hepatic T E cells or T CM cells are the main contributors to protracted T cell immunity and to confirm whether the preservation of T E cells requires a persistent Ag depot. It follows that adjuvants that create an Ag depot or a recombinant virus generating persistent latent infection [68] might help to maintain multi-functional T EM cells in the peripheral tissue. The highly successful yellow fever vaccine targets four different TLRs located on distinct sub-populations of DCs, each with its own unique booster-effect on the immune system [69] . Hence, a combination of malaria Ags with multiple component adjuvants that target different TLRs could lead to a T H1 /T H2 balance favoring long-lived Ab production and long-lived T cell memory. Other adjuvants such as Iscomatrix (cage-like structures consisting of saponin, phospholipid and cholesterol) could also be considered, to enhance Ab as well as CD4 and CD8 T cell responses in humans [70] .
Alternatively, vaccine platforms with intrinsic immunostimulatory properties could be employed to achieve a similar broad activation of humoral and cellular immunity. Combining RTS,S with a viral vector expressing either CS protein or other appropriate sporozoite or liver-stage Ags in a prime and boost regimen could induce both strong Ab and CD4 and CD8 T cell responses leading to more durable protection [71] . In support, a study in macaques demonstrated that two doses of RTS,S following an adenovirus 35 CS-protein priming immunization retained the RTS,S-induced Ab response while promoting a markedly higher CD4 T-cell response that remained elevated for about 2 months [72] .
Finally, a subunit vaccine will need to be immunogenic in humans, who generally exhibit a high degree of genetic Table 1 . Outstanding issues in malaria vaccine development Ab-mediated immunity Refs Identify mechanisms that maintain high titers of CS-protein-specific Abs for a prolonged period of time [33] [34] [35] [36] 66, 67, 69] Determine the role of Abs specific for non-CS-protein sporozoite Ags [16, 73, 74] Establish the contribution to protection of Ab responses targeting malaria proteins expressed on the surface of infected hepatocytes [75] Identify mechanisms to induce production of high-avidity Abs [38] T cell-mediated immunity Identify the key sporozoite and liver-stage Ags that stimulate protective CD4 and CD8 T cell-mediated immunity [23] [24] [25] 64 ] Determine if there is a requirement for persisting CD4/CD8 T E cells or CD4/CD8 T CM cells (or both) for long-term protection [50, 51, 54, 58, 59, 61, 76] Establish whether there is a need for chronic stimulation from a persisting Ag depot to maintain long-lived intra-hepatic CD4/CD8 T E cells [36, 49, 60, 61] Characterize the relative contribution of multi-functional CD4/CD8 T cells versus unifunctional CD4/CD8 T cells in conferring protection [27, 41, 42] Identify the primary site (liver or lymph node draining the liver) of pre-erythrocytic stage Ag-specific CD4/CD8 T cell activation [15, 51, 54, 69] Determine whether CD4/CD8 T cells induced by subcutaneous or intramuscular immunization with subunit vaccines migrate to the liver [51] Identify a cross-presentation pathway that can be targeted by exogenous Ag to activate CD8 T cells [54, 77, 78 ] Establish whether CD4 T FH cells promote the differentiation of pre-erythrocytic stage-specific B M cells and long-lived PC cells [33] Determine whether regulatory T cells inhibit responses to pre-erythrocytic stage Ags [7, [44] [45] [46] [47] 56] Elucidate to what extent host and parasite genetic diversity affect CD4/CD8 T-cell responses to pre-erythrocytic stage Ags diversity. One approach to overcoming genetic restriction would be to employ a subunit vaccine containing epitopes from multiple antigens, including universal epitopes that bind to multiple HLA types. In addition, it might be possible to choose epitopes that are restricted by HLA supertypes.
In summary, a successful pre-erythrocytic stage malaria vaccine will have to induce a durable antibody response against the sporozoite and a protracted CD4 and CD8 protective T cell response against the liver stages of the parasite. These goals should be achievable using the appropriate immunization regimens in conjunction with newly developed adjuvants and vaccine delivery vehicles. A malaria vaccine will also have to address human genetic diversity, possibly by including universal T cell epitopes, as well as the genetic diversity in the parasite itself. Clearly, we are moving closer to the development of a successful malaria vaccine, but much work remains to be done.
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